CD79b-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


12»
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Journal:  Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration. (Pubmed Central) -  Dec 12, 2025   
    Interestingly, 2 of the 3 CNSL patients achieved a complete response to pola-based treatment. In summary, these data indicate pola is effective against pre-clinical CNSL models and can partially penetrate the BBB in CNSL patients, which together provide support for the evaluation of pola-based treatment in future clinical trials of primary and secondary CNSL.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
    Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data () -  Dec 5, 2025 - Abstract #ASH2025ASH_10089;    
    In summary, these data indicate pola is effective against pre-clinical CNSL models and can partially penetrate the BBB in CNSL patients, which together provide support for the evaluation of pola-based treatment in future clinical trials of primary and secondary CNSL. All patients received at least 3 cycles of Pola-based regimens, with the vast majority administered Pola-R-CHP, consisting of polatuzumab vedotin (1.8 mg/kg, intravenous [IV], day 1); rituximab (375 mg/m
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Journal, IO biomarker:  B cell receptor silencing reveals origin and dependencies of high-grade B cell lymphomas with MYC and BCL2 rearrangements. (Pubmed Central) -  Jul 1, 2025   
    IGHUND HGBCL-DH-BCL2 models exhibit reduced sensitivity to the CD79B-targeting antibody-drug conjugate Polatuzumab-vedotin. Collectively, HGBCL-DH-BCL2 commonly arises from isotype-switched t(14;18)+ germinal center B cells, which edit IG light chains, fueling intra-clonal diversification, BCR extinction, and t(8;22) while maintaining IGH dependence, with clinical implications.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    POLATUZUMAB VEDOTIN IN A PATIENT WITH PREVIOUSLY UNTREATED BURKITT LYMPHOMA () -  May 15, 2025 - Abstract #EHA2025EHA_3514;    
    Polatuzumab shows potential as a promising new agent for inclusion in the first-line treatment of BL. Further research is needed to fully evaluate its efficacy in this subset of patients.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Journal:  Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC. (Pubmed Central) -  Apr 3, 2025   
    The ADC comprises native polatuzumab as the targeting antibody and a linker-payload consisting of a RKAA-peptide linker and MMAE...In summary, the data show that our novel site-specific bioconjugation technology enabled the generation of an anti-CD79b-RKAA-MMAE ADC with highly favorable biophysical properties and a greatly improved therapeutic index by a factor of 4 to 6 compared with PV. The ADC may therefore represent a safe and efficacious alternative for patients with diffuse large B-cell lymphoma.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Pola-Based Framework Regimen Treating DLBCL in Real World at Renji Hospital of China () -  Dec 7, 2024 - Abstract #ASH2024ASH_9766;    
    Polatuzumab vedotin (Pola), an antibody-drug conjugate targeting CD79b, is a newly-developed drug that authentically improve the therapeutic effect of DLBCL...The adverse effects, particularly immune-compromised pneumonia and agranulocytosis, necessitate meticulous monitoring and management. These findings highlight the importance of tailored therapeutic approaches to improve patient outcomes.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis () -  Dec 7, 2024 - Abstract #ASH2024ASH_8563;    
    The median DOR was 7.3 months and median DOCR was 8.9 months in the overall patients. Interestingly, among the 21 patients who achieved CR, only one patient experienced subsequent disease progression, suggesting that regardless of the line of treatment, once CR is achieved based on regimes including POLA, patients may experience durable disease remission.Conclusion : POLA-based regimens are associated with durable disease remissions and prolonged disease-free survival after achieving CR, underscoring the imperative for the prompt identification of high-risk patients and the initiation of POLA-based regimens at an early stage.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin (Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)) -  Nov 6, 2024 - Abstract #ASH2024ASH_1433;    
    ORR and CRR to pola-containing therapy in the frontline setting did not differ significantly by COO subtype, but longer follow-up of larger cohorts is needed to clarify the predictive role of COO by Hans algorithm in this setting, especially considering the PFS advantage with polaRCHP in POLARIX was not associated with significant differences in ORR or CRR. Overall, clinicians should consider factoring COO subtype into treatment decisions regarding pola-containing regimens, and studies of pola-based therapies should stratify patients and report outcomes by COO subtype.
  • ||||||||||  Review, Journal:  The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. (Pubmed Central) -  Jul 27, 2024   
    Combination strategies with chemotherapy, immunotherapy, and ADCs are currently under investigation with encouraging results in first-line or subsequent lines of treatment. In the following review, we focus on the structure of BsAbs, the mechanism of action, clinical efficacy, and the mechanisms of resistance to BsAbs.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Post-translational modifications regulate sensitivity to Polatuzumab Vedotin in DLBCL (Section 21; Poster Board #8) -  Mar 14, 2023 - Abstract #AACR2023AACR_8302;    
    Importantly, KLHL6 is heavily mutated across all germinal center derived malignancies, is more highly expressed in germinal center B-cells than other members of the B-cell lineage, and plays an unknown role in the development of autoimmune diseases. Further work will give evidence for the target of KLHL6 mediated ubiquitination and will show how this gene can drive lymphoma and autoimmune disease development in the germinal center.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma (Section 6; Poster Board #11) -  Mar 14, 2023 - Abstract #AACR2023AACR_7732;    
    To further investigate the molecular parameters of the relative sensitivity of polatuzumab vedotin. Gene expression profiling of those PDX models and their sensitivity to polatuzumab vedotin were conducted, we found that the expression level of BCL-XL was correlated with reduced sensitivity to polatuzumab vedotin.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC () -  Nov 29, 2022 - Abstract #ASH2022ASH_7180;    
    Therefore, the tolerability in rodents and non-human primates is at least 3 and 8 times higher when compared to historical safety data of Polivy®. Using the HNSTD derived from repeat dose non-human primate toxicity study (24 mg/kg) and the MED calculated from single dose rodent efficacy studies (1 mg/kg) an impressive TI of 24 can be calculated for ARC-02 which is substantially higher than the TI of Polivy®.These encouraging results obtained so far indicate that ARC-02 a) has very favorable biophysical properties, b) shows a consistent and highly defined DAR, c) is highly stable in vitro and in vivo, d) is highly potent and efficacious in multiple tumor models and e) has improved tolerability in rodents and non-human primates and f) shows an impressive improvement in TI and ultimately warrant further development of ARC-02.
  • ||||||||||  Polivy (polatuzumab vedotin-piiq) / Roche
    Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (Hall D (Ernest N. Morial Convention Center)) -  Nov 4, 2022 - Abstract #ASH2022ASH_6696;    
    P3
    However, several noticeable factors that could affect the cost-effectiveness profile of pola-R-CHP therapy should be considered in decision-making. The follow-up period of the POLARIX trial was relatively short, and mature survival data would be required to fully evaluate the value of pola in the treatment of newly diagnosed DLBCL.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Has R-CHOP Really Been Replaced as Initial Therapy of Diffuse Large B-cell Lymphoma (DLBCL)? () -  Sep 22, 2022 - Abstract #SOHO2022SOHO_389;    
    Despite this massive increase in biologic understanding, the standard of care for most patients has been rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP) for more than 20 years...More recently, a series of studies leveraging cell of origin status, attempting a “precision approach” to DLBCL have evaluated the addition of drugs like bortezomib (targeting NF kappa B), ibrutinib (targeting Brutons tyrosine kinase), and lenalidomide (targeting cereblon) to RCHOP for patients with ABC subtype of DLBCL...It is disappointing that RCHP-polatuzumab is a subtype-agnostic treatment, not informed by our improved understanding of the heterogeneity of DLBCL. However, taken together, RCHPpolatuzumab will likely replace RCHOP as preferred upfront treatment in intermediate and high clinical risk subsets of DLBCL, at least until future precision medicine approaches utilizing mutation-defi ned subsets of DLBCL are developed.2